Early Experience with a Novel Hemodialysis System used for PIRRT Demonstrates Clinical Management at Lower Cost than CRRT and IHD



Sevag Demirjian MD¹, Matthew Layne¹, Glenn M Chertow MD², Luis Alvarez MD, PhD³

¹Cleveland Clinic, ²Stanford University, ³Palo Alto Medical Foundation



Cleveland Clinic

Cleveland Clinic

INTRODUCTION

- The need for providing dialysis to patients in the ICU has increased over time
- Delivery of this care is challenging to health care systems \bullet (HCS) both in costs and logistics

METHODS


Prospective pilot study of the Tablo[®] Hemodialysis System in 37 critically ill patients deemed appropriate by the physician with no specific inclusion/exclusion criteria

RESULTS

- All 79 treatments were tailored to specific patient need with no specific guidance \bullet on prescription
- In 7 cases treatment was terminated early due to non-clinical reasons, including \bullet patients needs for testing, procedures or machine availability
- 58 (82%) of treatments achieved their target dose of dialysis and UF
- Causes of early termination were related to access issues, clotting, hemodynamic instability or other related factors
- The cost of PIRRT with Tablo was found to be lower than both CRRT and IHD with a traditional dialysis machine
- 79 treatments performed ranging from 4-12 hours using a $Q_{\rm B}$ \bullet between 200-300 ml/min and Q_{D} between 100-300 ml/min while recording treatment results and staffing and supply costs

37 (19/18)
60 (16)
92 (33)
79
100
6 (4-12)
255 (200-300)
300 (100-300)
1.2 (0-3)





DESCRIPTION OF TABLO

The Tablo Hemodialysis System is an all in one device indicated for use in the hospital and clinic that is designed to expand how, when and where dialysis can be performed. It's unique features include:

- An integrated water purification system
- Ability to produce prescribed dialysate on demand
- Simplified user interface making it easy to learn and use
- Two-way wireless connectivity to simplify documentation



CONCLUSION

At the Cleveland Clinic, we demonstrated that Tablo can offer clinically effective transitional hemodialysis in a critically ill cohort, many whom were not able to be anticoagulated. These data suggest that Tablo could provide increased functionality and flexibility for staff constrained ICUs while achieving diverse clinical goals and significantly reducing cost.

